Kytopen provides Flowfect Discover™ platform to explore and optimize conditions in a 96-well format.
Published
Signal category
Products & Services
Quote
“Flowfect Discover™ platform helps explore and optimize conditions in a 96-well format”
— Kytopen team
Company
Kytopen
Open cells to new possibilities: Accelerating cell therapy processes from discovery through manufacturing with Flowfect®
- Industry
- Biotechnology Research
- Location
- Cambridge, US
- Company size
- 26 employees
Kytopen is focused on the development and commercialization of groundbreaking genome engineering platforms for expediting the discovery, development, and manufacture of gene-modified cell therapies. Developed at MIT, the Flowfect® platform, harmonizing microfluidics and automation, revolutionizes the delivery of genome engineering materials to cells of therapeutic interest in an expeditious, scalable, and economically advantageous manner compared to current alternatives. In May 2023, Kytopen unveiled the Flowfect Discover™, an automated high-throughput genome engineering platform, and disclosed strategic partnerships with industry-leading Contract Development and Manufacturing Organizations (CDMOs) and translational academic medical centers. By combining Flowfect Discover™ with the Flowfect Tx™ large-scale delivery device in process development workflows, developers can now surmount manufacturing challenges during the discovery stage, fostering swifter and more cost-effective innovation.
Founded 2017